Clinical trials: Respiratory
Asthma
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma.
- Trial name
- NCT01686633
- Testing
- Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,040 people
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
This clinical trial is studying the newly licensed RSV vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living…
- Trial name
- NCT06077149
- Testing
- RSV vaccine
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
Extensive-Stage Small Cell Lung Cancer
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
This proposed trial will investigate the combination of amrubicin and carboplatin in the first-line treatment of patients with extensive-stage small cell lung cancer (ES- SCLC).
- Trial name
- NCT01076504
- Testing
- Amrubicin, Carboplatin, Pegfilgrastim
- Where
- 20 sites in United States
- Volunteers
- 81 people
- Sponsor
- SCRI Development Innovations, LLC
Exercise Induced Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
1. The primary objective of this study is: To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced…
- Trial name
- MIA (NCT00989833)
- Testing
- budesonide, terbutaline, budesonide/formoterol
- Where
- 10 sites in Norway, Sweden
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Acute Respiratory Distress Syndrome, Acute Lung Injury
Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury
Lung units which participate in gas exchange are known as 'recruited' lung. Patients with lung injury suffer from a proportion of units which do not participate in gas exchange (i.e.
- Trial name
- Recruitment (NCT00830284)
- Testing
- Recruitment maneuver
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Children's Hospital
Obstructive Sleep Apnea
Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)
The primary endpoints for this study are that the AL validation will 1) achieve a sensitivity of greater than 80% for AHI values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating…
- Trial name
- NCT00354614
- Testing
- ApneaLink Sleep Screener
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- ResMed
Non-small Cell Lung Cancer
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs.
- Trial name
- NCT02730247
- Testing
- ramucirumab, nab-paclitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liza Villaruz, MD
Colon Cancer, Lung Cancer
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Diagnostic delays in ambulatory care are often due to breakdowns of related care processes. Electronic systems can improve follow-up and reduce delays by detecting missed appointments or incomplete procedures so that patients are…
- Conditions
- Colon Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01346839
- Testing
- Contact Intervention
- Where
- 2 sites in United States
- Volunteers
- 1,256 people
- Sponsor
- Baylor College of Medicine
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cystic Fibrosis, Pseudomonas Aeruginosa
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic candidate administered…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection
- Trial name
- SWARM-Pa (NCT04596319)
- Testing
- AP-PA02
- Where
- 20 sites in United States
- Volunteers
- 29 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Asthma
Impact of Adherence to Treatment in Asthma Control
This survey aims to analyze how adherence to treatment, using Ask-20 questionnaire and prescription count, influences level of asthma control in a sample of patients with severe and moderate-mild asthma.
- Trial name
- NCT01455545
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Sociedad Española de Neumología y Cirugía Torácica
Pulmonary Embolism, Deep Vein Thrombosis
Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System
The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF.
- Trial name
- NCT02394912
- Testing
- vena cava filter implantation (LUMIFI with Crux VCF System)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Volcano Corporation
Covid19
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.
- Trial name
- PARACOR-19 (NCT04883528)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease…
- Trial name
- NCT00556712
- Testing
- erlotinib [Tarceva]
- Where
- 133 sites in Australia, Austria and 26 more
- Volunteers
- 889 people
- Sponsor
- Hoffmann-La Roche
Cystic Fibrosis, Lung Transplant
Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Lung transplantation is a life saving procedure for patients with a terminal lung disease such as cystic fibrosis. Approximately, one in 3,500 children in the United States are born with cystic fibrosis each year with the…
- Trial name
- NCT00908830
- Volunteers
- 10 people
- Sponsor
- University of Michigan
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.